Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis

Vaccine

Volumn 33, Issue 35, 2015, Pages 4349-4358

  Ramezanpour, Bahar ^a,c   Pronker, Esther S ^b   Kreijtz, Joost H C M ^a   Osterhaus, Albert D M E ^a,d   Claassen, E ^a,c,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Viroclinics Biosciences BV   (Netherlands)

^c ATHENA INSTITUTE   (Netherlands)

^d Artemis One Health   (Netherlands)

Author keywords

Influenza virus; Modified vaccinia virus Ankara (MVA); Pre pandemic and Pandemic vaccine; Vaccine production platform; Vaccine technology platform; Virus vectored vaccine

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; COMPARATIVE STUDY; CROSS REACTION; DRUG COST; DRUG QUALITY; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; MODIFIED VACCINIA VIRUS ANKARA; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; VACCINE PRODUCTION; VACCINIA VIRUS; CHEMISTRY; ECONOMICS; GENETICS; IMMUNOLOGY; INFLUENZA, HUMAN; PANDEMICS; PROCEDURES; STANDARDS; VACCINATION;

HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; VACCINATION; VACCINIA VIRUS;

EID: 84939566977     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.04.086     Document Type: Article

References (62)

1. Draper S.J., Cottingham M.G., Gilbert S.C. Utilizing poxviral vectored vaccines for antibody induction-progress and prospects. Vaccine 2013, 31:4223-4230.
2. Wong S.S., Webby R.J. Traditional and new influenza vaccines. Clin Microbiol Rev 2013, 26:476-492.
3. TNIoAaID (2013) Types of Vaccines. Vaccinesgov, . http://www.vaccines.gov/more_info/types/.
4. Tomori O. From smallpox eradication to the future of global health: innovations, application and lessons for future eradication and control initiatives. Vaccine 2011, 29(Suppl. 4):D145-D148.
5. de Swart R.L., Duprex W.P., Osterhaus A.D. Rinderpest eradication: lessons for measles eradication?. Curr Opin Virol 2012, 2:330-334.
6. Roth G.A., Fee E. Images of health, smallpox: the first vaccine. Am J Public Health 2011, 101:1217.
7. Liu M.A. Immunologic basis of vaccine vectors. Immunity 2010, 33:504-515.
8. Tarahomjoo S. Development of vaccine delivery vehicles based on lactic acid bacteria. Mol Biotechnol 2012, 51:183-199.
9. Teigler J.E., Phogat S., Franchini G., Hirsch V.M., Michael N.L., Barouch D.H. The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J Virol 2014, 88:1809-1814.
10. Cottingham M.G., Carroll M.W. Recombinant MVA, vaccines: dispelling the myths. Vaccine 2013, 31:4247-4251.
11. Kreijtz J.H., Gilbert S.C., Sutter G. Poxvirus vectors. Vaccine 2013, 31:4217-4219.
12. Rollier C.S., Reyes-Sandoval A., Cottingham M.G., Ewer K., Hill A.V. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011, 23:377-382.
13. Moss B. Reflections on the early development of poxvirus vectors. Vaccine 2013, 31:4220-4222.
14. Gomez C.E., Najera J.L., Krupa M., Perdiguero B., Esteban M. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 2011, 11:189-217.
15. Volz A., Sutter G. Protective efficacy of modified vaccinia virus Ankara in preclinical studies. Vaccine 2013, 31:4235-4240.
16. Gilbert S.C. Clinical development of modified vaccinia virus Ankara vaccines. Vaccine 2013, 31:4241-4246.
17. Altenburg A.F., Kreijtz J.H.C.M., de Vries R.D., Song F., Fux R., Rimmelzwaan G.F., et al. Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 2014, 6.
18. EMA Imvanex, modified vaccinia Ankara virus. EMA Sci Med Health 2013.
19. Kreijtz J.H., Suzer Y., Bodewes R., Schwantes A., van Amerongen G., Verburgh R.J., et al. Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J Gen Virol 2010, 91:2745-2752.
20. Rimmelzwaan G.F., Kreijtz J.H.C.M., Suezer Y., Schwantes A., Osterhaus A.D., Sutter G. Preclinical evaluation of influenza vaccines based on replication-deficient poxvirus vector MVA. Procedia Vaccinol 2011, 4.
21. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12:1032-1040.
22. Bender B.S., Rowe C.A., Taylor S.F., Wyatt L.S., Moss B., Small P.A. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol 1996, 70:6418-6424.
23. Berthoud T.K., Hamill M., Lillie P.J., Hwenda L., Collins K.A., Ewer K.J., et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011, 52:1-7.
24. Powell T.J., Peng Y., Berthoud T.K., Blais M.E., Lillie P.J., Hill A.V.S., et al. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLOS ONE 2013, 8:e62778.
25. Kangas J., Kurttila M., Kajanus M., Kangas A. Evaluating the management strategies of a forestland estate--the S-O-S approach. J Environ Manage 2003, 69:349-358.
26. Görener A., Toker K., Uluçay K. Application of combined SWOT and AHP: a case study for a manufacturing firm. Procedia Soc Behav Sci 2012, 58:1525-1534.
27. Kahraman C., Demirel N.C., Demirel T. Prioritization of e-government strategies using a SWOT-AHP analysis: the case of Turkey. Eur J Inf Syst 2007, 16:284-298.
28. Saaty T.L. The analytic hierarchy process 1980, McGraw-Hill, New York.
29. Hill T., Westbrook R. SWOT analysis: its time for a product recall. Long Range Plan 1997, 30:46-52.
30. Saaty T.L. Decision making for leaders: the analytical hierarchy process for decisions in a complex world. Anal Hierarchy Process Ser 1982, 2:71-74.
31. Saaty T.L. Decision making with the analytic hierarchy process. Int J Serv Sci 2008, 1:83-98.
32. Lee S., Walsh P. SWOT and AHP hybrid model for sport marketing outsourcing using a case of intercollegiate sport. Sport Manag Rev 2011, 14:361-369.
33. Hampson A.W. Vaccines for pandemic influenza, the history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann Acad Med Singap 2008, 37:510-517.
34. Plosker G.L. A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel(R)]. Drugs 2012, 72:1543-1557.
35. Keating G.M., Plosker G.L., Lyseng-Williamson K.A. A/H5N1 prepandemic influenza vaccine (Vepacel(R)): a guide to its use. BioDrugs 2012, 26:425-430.
36. Vajo Z., Tamas F., Sinka L., Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010, 375:49-55.
37. EMA Adjupanrix (previously Pandemic influenza vaccine (H5N1)) (split virion, inactivated, adjuvanted) 2009, EMA http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001206/human_med_001214.jsp&mid=WC0b01ac058001d124.
38. Sedova E.S., Shcherbinin D.N., Migunov A.I., Smirnov Iu A., Logunov D., Shmarov M.M., et al. Recombinant influenza vaccines. Acta Nat 2012, 4:17-27.
39. Couch R.B., Patel S.M., Wade-Bowers C.L., Nino D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS ONE 2012, 7:e49704.
40. EMA Focetria, influenza vaccine (H1N1) (surface antigen, inactivated, adjuvanted) 2009, EMA http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000710/human_med_000796.jsp&mid=WC0b01ac058001d124.
41. Cox M.M. Recombinant protein vaccines produced in insect cells. Vaccine 2012, 30:1759-1766.
42. Lopez-Macias C. Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic. Hum Vaccin Immunother 2012, 8:411-414.
43. Tang X.C., Lu H.R., Ross T.M. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge. Viral Immunol 2011, 24:311-319.
44. Lopez-Macias C., Ferat-Osorio E., Tenorio-Calvo A., Isibasi A., Talavera J., Arteaga-Ruiz O., et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011, 29:7826-7834.
45. Nair H., Lau E., Brooks W., Seong A., Theodoratou E., Zgaga L., et al. An evaluation of the emerging vaccines against influenza in children. BMC Public Health 2013, 13 Suppl(3):S14.
46. Tripp R.A., Tompkins S.M. Virus-vectored influenza virus vaccines. Viruses 2014, 6:3055-3079.
47. Rudenko L., van den Bosch H., Kiseleva I., Mironov A., Naikhin A., Larionova N., et al. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine 2011, 29 Suppl 1:A40-A44.
48. Carter N.J., Curran M.P. Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 2011, 71:1591-1622.
49. Khurana S., Chearwae W., Castellino F., Manischewitz J., King L.R., Honorkiewicz A., et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010, 2:15ra15.
50. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375:56-66.
51. Ferraro B., Morrow M.P., Hutnick N.A., Shin T.H., Lucke C.E., Weiner D.B. Clinical applications of DNA vaccines: current progress. Clin Infect Dis 2011, 53:296-302.
52. Ledgerwood J.E., Hu Z., Gordon I.J., Yamshchikov G., Enama M.E., Plummer S., et al. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol 2012, 19:1792-1797.
53. Smith L.R., Wloch M.K., Ye M., Reyes L.R., Boutsaboualoy S., Dunne C.E., et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010, 28:2565-2572.
54. Kreijtz J.H., Goeijenbier M., Moesker F.M., van den Dries L., Goeijenbier S., De Gruyter H.L.M., et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis 2014, 14:1196-1207.
55. Clegg C.H., Rininger J.A., Baldwin S.L. Clinical vaccine development for H5N1 influenza. Expert Rev Vacci 2013, 12:767-777.
56. Barfod M.B., Leleur S. Alternative procedures for deriving value functions based on point scales and AHP. Technical note, Centre for Traffic and Transport 2007, Technical University of Denmark.
57. Goodwin P., Wright G. Decision Analysis for Management Judgment 1998, Wiley.
58. Price P.J., Torres-Dominguez L.E., Brandmuller C., Sutter G., Lehmann M.H. Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling. Vaccine 2013, 31:4231-4234.
59. Draper S.J., Heeney J.L. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010, 8:62-73.
60. EMA Imvanex, modified vaccinia Ankara virus 2013, EMA http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002596/human_med_001666.jsp&mid=WC0b01ac058001d124.
61. GlobalData Influenza vaccines therapeutics - pipeline assessment and market forecast to 2018 2011, Research and Markets Abstract available at http://www.researchandmarkets.com/research/67d93b/influenza_vaccines.
62. Osterhaus ADME ARCAS: Analysis of the route to commercialisation of MVA based influenza vaccines 2012, ARCAS. Erasmus Universitair Medisch Centrum: European Research Council.